CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cotinga Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cotinga Pharmaceuticals Inc
The Mogenson Centre
100 Collip Cir Suite 230B
Phone: (519) 858-5157p:519 858-5157 LONDON, ON  N6G 4X8  Canada Ticker: COTCOT

Business Summary
Cotinga Pharmaceuticals Inc, formerly Critical Outcome Technologies Inc (COTI) is a Canada-based clinical-stage biopharmaceutical company. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. The Company's initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
7/31/20194/30/2019Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board John C.Drake 11/1/2008 2/20/2007
President, Chief Executive Officer, Director AlisonSilva 1/1/2017 5/14/2015
Chief Financial Officer VictorHugo 7/20/2018 7/20/2018
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 10 (As of 4/30/2009)
Outstanding Shares: 21,986,415 (As of 7/31/2019)
Stock Exchange: CVE
Fax Number: (519) 858-5179


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 18, 2019